Clinical blockade of PD1 and LAG3 — potential mechanisms of action

Abstract

Dysfunctional T cells can render the immune system unable to eliminate infections and cancer. Therapeutic targeting of the surface receptors that inhibit T cell function has begun to show remarkable success in clinical trials. In this Review, we discuss the potential mechanisms of action of the clinical agents that target two of these receptors, programmed cell death protein 1 (PD1) and lymphocyte activation gene 3 protein (LAG3). We also suggest correlative studies that may define the predominant mechanisms of action and identify predictive biomarkers.

The immune network in thyroid cancer

“…53 Targeting these mediators could be exploited to block TC growth, since this strategy has been already developed for other tumors. 116 Moreover, boosting anticancer immune responses by blocking immunosuppressive molecules (TGF-b, IL-10, CTLA-4, PD-1 and PD-L1) expressed either by cancer cells or by tumor-infiltrating immune cells 117 and cytolytic viruses approaches 51 appear promising therapeutic strategies in different tumors, including TC.…”

Inhibition of yes‐associated protein down‐regulates PD‐L1 (CD274) expression in human malignant pleural mesothelioma

“…Immunotherapy targeting the immune checkpoint programmed death‐1 (PD‐1)/PD‐ligand (L) 1 axis has been used to treat various cancers including non‐small‐cell lung cancer, melanoma, renal cell carcinoma and Hodgkin lymphoma 6, 7, 8, 9, 10. Recently, PD‐1/PD‐L1 inhibitors were also used to treat patients with advanced MPM, and several clinical trials are ongoing 11, 12.…”

Pembrolizumab in the Treatment of Metastatic Melanoma

“…Для того чтобы представлять особенности развития противоопухолевого ответа и некоторые особенности неже-лательных явлений, коротко изложим предполагаемый механизм действия, который в зарубежной и русскоязычной литературе ранее был многократно описан [2,[13][14][15][16].…”